- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04911231
Clinical Validation of a Mobility Monitor to Measure and Predict Health Outcomes (MOBILISE-D)
Validating Digital Mobility Assessment Using Wearable Technology - the Mobilide-D Clinical Validation Study
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
The study plans to include patients in two groups, both acute (during hospital stay after hip fracture) and subacute (up to 6 months post hip fracture from waiting lists). With this strategy, it is possible to have the life-course of PFF (first 12 months and the time after). Acute phase inclusion is defined as inclusion start on first days after surgery and will be completed within the first 14 days. Subacute phase inclusion is defined as inclusion from waiting lists, where baseline will be conducted up to 6 months after hip fracture surgery.
Fear of falling will be tested using a single question during the acute phase and the short form of the fall efficacy scale international (Short FES-I) for all other assessments. For the acute recruited group of patients (2/3 of included participants), sensor recordings will be made on patients from hospital stay (attached on day 2 after surgery) and continue after discharge (until day 9 depending on battery capacity of the sensors) to be able to monitor and describe DMOs from about 2 days during hospital stay and several days after discharge to be able to evaluate improvement during the acute rehabilitation process. For all other assessments, sensor recordings will be collected for a minimum of 7 full continuous days in line with the core data collection manual.
Hip fracture patients will be tested for sarcopenia according to the updated definitions of the European and US-American working groups. In centers where bioimpedance measurements are possible, participants will receive this measurement as part of the core data collection.
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Contatto studio
- Nome: Hubert Blain, PD PH
- Numero di telefono: 00334 67 33 67 94
- Email: h-blain@chu-montpellier.fr
Backup dei contatti dello studio
- Nome: Stephanie Miot, PD
- Numero di telefono: 00334 67 33 09 67
- Email: s-miot@chu-montpellier.fr
Luoghi di studio
-
-
-
Montpellier, Francia, 34295
- Reclutamento
- Centre Hospitalier Universitaire de Montpellier
-
Contatto:
- Hubert Blain, PD PH
- Numero di telefono: 0033 467336790
- Email: h-blain@chu-montpellier.fr
-
Contatto:
- Miot Stephanie, PD
- Email: s-miot@chu-montpellier.fr
-
Sub-investigatore:
- François CANOVAS, PD PH
-
Sub-investigatore:
- Louis DAGNEAUX, PD
-
Montpellier, Francia, 34000
- Reclutamento
- Polyclinique Saint-Roch
-
Contatto:
- Marion Bertrand Marchand, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Aged 45 or over
- Surgical treatment (fixation or arthroplasty) for a low-energy fracture of the proximal femur (ICD-10 diagnosis S72.0, S72.1, S72.2) as diagnosed on X-rays of the hip and pelvis. Between 3 days and 52 weeks post-surgery
be able to walk 4 meters
-.be available for 24 months following the fracture,
- be able to read and understand the briefing note and complete questionnaires feedback
- express their will and sign a consent to participate in follow-up testing, and to wear the motion sensor
- The patient must be a member or beneficiary of a health insurance plan
Exclusion Criteria:
Occurrence of one of the following events in the 3 months preceding the consent enlightened
- subject with a history of myocardial infarction,
- Subject hospitalized for unstable angina,
- Subject with a history of stroke,
- Subject with a history of coronary bypass surgery (PAC),
- Subject having had percutaneous coronary intervention (PCI),
Subject having had a cardiac resynchronization therapy device implanted (CRTD),
- Other criteria for non-inclusions
- Subject with active treatment for cancer or other malignant disease,
- Subject with uncontrolled congestive heart disease (NYHA class> 3),
- Subject with acute psychosis or major psychiatric disorders
- Subject with continued drug addiction.
- Subject unable to walk prior to hip fracture treatment.
- The patient is participating in another interventional category I study,
- l All categories of persons particularly protected under the law French (adults under guardianship, guardianship or safeguard of justice…. articles L1121-8 - L1121-5 - L1121-6 - L1121-7 - L1121-9 of the Health Code Public)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Change in the functional component score of the Late-Life Functional Disability Index (LLFDI), that goes from 0 to 100, during 24 months follow-up.
Lasso di tempo: 24 months
|
Measured at baseline, 6, 12, 18 and 24 months
|
24 months
|
Admission to a care home
Lasso di tempo: 6 months
|
Assessed from patient records at 6 months follow-up
|
6 months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Hubert Blain, PD PH, University Hospital, Montpellier
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- RECHMPL20_0700
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .